Idera Pharmaceuticals Announces Closing of Public Offering of Common Stock
February 19 2015 - 3:21PM
Idera Pharmaceuticals, Inc. (Nasdaq:IDRA) ("Idera" or the
"Company") today announced the closing of its previously announced
underwritten public offering of 23,000,000 shares of common stock
at an offering price of $3.75 per share. The shares of common stock
in the offering include 3,000,000 shares issued upon the exercise
in full by the underwriters of their option to purchase additional
shares at the offering price. The gross proceeds to Idera from this
offering total $86.25 million, before underwriting discounts and
commissions and offering expenses. Goldman, Sachs & Co. and
J.P. Morgan acted as joint bookrunning managers for the offering.
Piper Jaffray & Co. acted as lead manager for the offering.
The offering was made pursuant to a shelf registration statement
previously filed with the Securities and Exchange Commission (the
"SEC") on May 12, 2014 and declared effective by the SEC on May 22,
2014. Copies of the final prospectus relating to the offering may
be obtained from the SEC's website at http://www.sec.gov, or from
Goldman, Sachs & Co., Attention: Prospectus Department, 200
West Street, New York, NY 10282, or by telephone at (866) 471-2526
or e-mail at prospectus-ny@ny.email.gs.com; or from J.P. Morgan,
c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717 (telephone: 866-803-9204).
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any of Idera's securities. No
offer, solicitation or sale will be made in any jurisdiction in
which such offer, solicitation or sale is unlawful.
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals is a clinical-stage biopharmaceutical
company developing a novel therapeutic approach for the treatment
of genetically defined forms of B-cell lymphoma and rare diseases.
Idera's proprietary technology involves using a Toll-like receptor
(TLR) targeting technology, to design synthetic
oligonucleotide-based drug candidates to act by modulating the
activity of specific TLRs. In addition to its TLR programs, Idera
is developing gene silencing oligonucleotides (GSOs) that it has
created using its proprietary technology to inhibit the production
of disease-associated proteins by targeting RNA.
CONTACT: Investor Contact
Robert Doody
Vice President, Investor Relations & Corporate Communications
484-639-7235
rdoody@iderapharma.com
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Apr 2023 to Apr 2024